Product Information

GABAPENTIN ER 300 MG TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.7249 per EA under NDC 31722009190. Its NADAC has been published 110 times since Jul 17, 2024.

FDA first approved this application on Feb 26, 2024. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the GABAPENTIN market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

GABAPENTIN ER 300 MG TABLET

GABAPENTIN
$0.7249per EA
High Outlier

Strength

300 mg/1

NDC

31722009190

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA218075

FDA Approved

2/26/2024

TE Code

AB2

On Market Since

2/26/2024

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for GABAPENTIN ER 300 MG TABLET has been published 110 times since Jul 17, 2024, and over the history we have for it it has declined 55.9%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7249 per EA
All-time high$2.2901 (Jun 11, 2025)
All-time low$0.7249 (Aug 19, 2026)
52-week high$2.1499
52-week low$0.7249
Median price$1.5397
Average price$1.6706
Largest weekly change+35.5% (Aug 21, 2024)
Weeks tracked110
Tracking sinceJul 17, 2024

Price History

1W

-13.0%

1M

-30.7%

3M

-40.0%

6M

-51.3%

1Y

-66.3%

3Y

N/A

5Y

N/A

All

-55.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the GABAPENTIN market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of GABAPENTIN ER 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN ER 300 MG TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.7249 per EA (NDC 31722009190), effective Aug 19, 2026.

How has the price of GABAPENTIN ER 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for GABAPENTIN ER 300 MG TABLET has declined 55.9%. It has been tracked across 110 weekly CMS publications since Jul 17, 2024.

What are the highest and lowest recorded NADAC prices for GABAPENTIN ER 300 MG TABLET?

Since Jul 17, 2024, the NADAC for GABAPENTIN ER 300 MG TABLET has ranged from a low of $0.7249 (Aug 19, 2026) to a high of $2.2901 (Jun 11, 2025), with a median of $1.5397 per EA.

Are there cheaper alternatives to GABAPENTIN ER 300 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of GABAPENTIN ER 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures GABAPENTIN ER 300 MG TABLET?

GABAPENTIN ER 300 MG TABLET (NDC 31722009190) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.